fluoropharma medical inc (FPMI:OTC BB)
fluoropharma medical inc (FPMI) Snapshot
|
Open
$0.75
|
Previous Close
$0.73
|
|
|
Day High
$0.79
|
Day Low
$0.71
|
|
|
52 Week High
09/20/12 - $1.19
|
52 Week Low
06/29/12 - $0.51
|
|
|
Market Cap
19.2M
|
Average Volume 10 Days
24.8K
|
|
|
EPS TTM
--
|
Shares Outstanding
24.4M
|
|
|
EX-Date
--
|
P/E TM
--
|
|
|
Dividend
--
|
Dividend Yield
--
|
Related News
fluoropharma medical inc (FPMI) Related Businessweek News
No Related Businessweek News Foundfluoropharma medical inc (FPMI) Details
FluoroPharma Medical, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of molecular imaging pharmaceuticals with primary applications in the area of cardiology. The company’s product portfolio includes BFPET, an imaging agent that has completed Phase Ia clinical trial in stress-testing for patients with presumptive or proven cardiac artery disease (CAD); and CardioPET, a molecular imaging agent, which has completed Phase I trials to assess myocardial metabolism for patients with coronary artery disease. It is also involved in developing VasoPET, a molecular imaging agent for the detection of ‘vulnerable’ coronary artery plaque in patients with CAD. FluoroPharma Medical, Inc. was founded in 2003 and is headquartered in Montclair, New Jersey.
fluoropharma medical inc (FPMI) Top Compensated Officers
fluoropharma medical inc (FPMI) Key Developments
FluoroPharma Medical, Inc. expected to report Fiscal Year 2012 results on May 23, 2013. This event was calculated by Capital IQ (Created on May 17, 2013).
FluoroPharma Medical, Inc. Presents at Taglich Brothers 10th Annual Small Cap Equity Conference, May-07-2013 09:30 AM. Venue: New York Athletic Club, 180 Central Park South (59th street @ 7th Avenue), New York, New York, United States. Speakers: Thijs Spoor, Chairman of the Board, Chief Executive Officer and President.
FluoroPharma Medical, Inc. announce that Dr. Joseph A. Pierro has been appointed to the Board of Directors. Dr. Pierro brings a wealth of expertise to FluoroPharma at an important time in the company's evolution. His career in health care and his work in imaging spans two decades. Dr. Pierro, a physician, has worked in the Pharmaceutical industry in global clinical research development and with the FDA across multiple therapeutic areas. Dr. Pierro is currently the Chief Medical Officer for North America at Biomedical Systems, where he is responsible for leading the Scientific Affairs groups, providing medical and regulatory guidance.
| Recently Viewed | |||
| FPMI:US | $0.79 USD | +0.06 |  |
| Company | Last | Change | |
| No competitor information is available for FPMI. | |||
| View Industry Companies | |||
Industry Analysis
FPMI
Industry Average
| Valuation | FPMI | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | -- | Not Meaningful |
| Price/Book | 29.3x |
|
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | -- | Not Meaningful |
Post a JobJobs
- Orlando, FL | Consult SoftPosted: May 22
- New York, NY |Posted: May 17
- San Francisco, CA | YelpPosted: May 02
- San Francisco, CA | YelpPosted: May 02
Sponsored Financial Commentaries
Sponsored Links
To contact FLUOROPHARMA MEDICAL INC, please visit www.fluoropharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.
Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.
